home / stock / capr / capr quote
Last: | $4.81 |
---|---|
Change Percent: | 0.21% |
Open: | $4.82 |
Close: | $4.81 |
High: | $4.85 |
Low: | $4.66 |
Volume: | 478,195 |
Last Trade Date Time: | 07/05/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$4.81 | $4.82 | $4.81 | $4.85 | $4.66 | 478,195 | 07-05-2024 |
$4.83 | $4.73 | $4.83 | $4.865 | $4.65 | 282,781 | 07-04-2024 |
$4.83 | $4.73 | $4.83 | $4.865 | $4.65 | 282,781 | 07-03-2024 |
$4.72 | $4.81 | $4.72 | $4.82 | $4.67 | 229,516 | 07-02-2024 |
$4.84 | $4.91 | $4.84 | $4.98 | $4.6 | 642,734 | 07-01-2024 |
$4.77 | $4.72 | $4.77 | $5.25 | $4.64 | 4,272,056 | 06-28-2024 |
$4.64 | $4.65 | $4.64 | $4.74 | $4.56 | 330,550 | 06-27-2024 |
$4.63 | $4.62 | $4.63 | $4.65 | $4.45 | 428,283 | 06-26-2024 |
$4.64 | $4.86 | $4.64 | $5.06 | $4.58 | 506,278 | 06-25-2024 |
$4.79 | $4.69 | $4.79 | $4.84 | $4.61 | 273,466 | 06-24-2024 |
$4.7 | $4.83 | $4.7 | $4.91 | $4.7 | 388,572 | 06-21-2024 |
$4.76 | $4.84 | $4.76 | $4.91 | $4.67 | 189,807 | 06-20-2024 |
$4.84 | $4.93 | $4.84 | $4.975 | $4.72 | 429,180 | 06-19-2024 |
$4.84 | $4.93 | $4.84 | $4.975 | $4.72 | 429,180 | 06-18-2024 |
$4.96 | $5.16 | $4.96 | $5.24 | $4.94 | 344,034 | 06-17-2024 |
$5.17 | $5.25 | $5.17 | $5.3487 | $5.03 | 218,595 | 06-14-2024 |
$5.29 | $5.05 | $5.29 | $5.41 | $5.035 | 175,388 | 06-13-2024 |
$5.06 | $5.59 | $5.06 | $5.77 | $4.93 | 638,765 | 06-12-2024 |
$5.55 | $5.38 | $5.55 | $5.77 | $5.37 | 337,373 | 06-11-2024 |
$5.41 | $5.17 | $5.41 | $5.4385 | $5.06 | 239,589 | 06-10-2024 |
News, Short Squeeze, Breakout and More Instantly...
Capricor Therapeutics Inc. Company Name:
CAPR Stock Symbol:
NASDAQ Market:
Capricor Therapeutics Inc. Website:
SAN DIEGO, July 01, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that the Company is set to join the Russell 2000 ® Index an...
-Results in Performance of the Upper Limb (PUL v2.0) Continue to Show Slowing of Disease Progression in Later-Stage DMD Patients- -Improvements Seen in Multiple Cardiac Endpoints Demonstrating Stabilization of Cardiac Function Over 3 Years of Treatment- -Pre-BLA Meeting with FDA...
SAN DIEGO, June 25, 2024 (GLOBE NEWSWIRE) -- In a release issued under the headline "Capricor Therapeutics Announces for the Treatment of Duchenne Muscular Dystrophy" on Tuesday, June 25th by Capricor Therapeutics, please note that the words "Pre-BLA Meeting with FDA for Deramiocel" were omitted ...